Does Medicare Cover Adalimumab-Adaz (Hyrimoz)? Part D Costs and Aid

Medicare does cover Hyrimoz (adalimumab-adaz), but only through Part D prescription drug plans, not Part B. Because Hyrimoz is a self-injected biosimilar to Humira, it sits on the pharmacy side of Medicare rather than the medical side. Whether your specific plan lists it, and what you pay at the counter, depends on your plan’s formulary and tier placement.

Which Part of Medicare Pays for Hyrimoz

Part D is the pathway. The Centers for Medicare and Medicaid Services placed adalimumab-adaz on its Self-Administered Drug Exclusion List effective June 2023, treating it as “apparent on its face” that patients inject it themselves at home.1CMS. Self-Administered Drug Exclusion List Part B covers drugs a clinician administers in an outpatient setting, so a self-injected biologic like Hyrimoz doesn’t qualify. The medical benefit cannot be billed for it, and any Medicare coverage runs through a standalone Part D plan or the drug portion of a Medicare Advantage plan.

Hyrimoz received an interchangeable designation from the FDA in April 2024, which lets pharmacists in most states substitute it for Humira without first contacting the prescriber.2FDA. Hyrimoz Interchangeability Approval Letter

Is Hyrimoz on Your Plan’s Formulary?

Not necessarily. As of 2025, 96% of standalone Part D plans and 88% of Medicare Advantage drug plans covered at least one Humira biosimilar, up sharply from 65% and 52% a year earlier.3HHS OIG. Most Medicare Part D Plans Formularies Included Humira Biosimilars for 2025 But the covered biosimilar may not be Hyrimoz. Research in Health Affairs Scholar found Hyrimoz on roughly 19.7% of Part D formularies as of July 2025, down from 31.2% in December 2023.4PMC. Adalimumab Biosimilar Formulary Coverage in Medicare Part D Express Scripts’ 2026 national preferred formulary does include adalimumab-adaz along with two other biosimilars.5Express Scripts. 2026 National Preferred Formulary

A small share of plans still cover only Humira itself. In 2025, 10% of Medicare Advantage drug plan enrollees and 1% of Part D enrollees were in plans that excluded all biosimilars.6AAPC. OIG Data Snapshot OEI-05-23-00520 Check your plan’s current formulary document and search for “adalimumab-adaz” or “Hyrimoz” before assuming it’s covered.

What You’ll Pay

Plans place adalimumab biosimilars on tier 4 or higher, almost always a specialty tier. That means coinsurance, a percentage of the drug’s cost, rather than a flat copay.4PMC. Adalimumab Biosimilar Formulary Coverage in Medicare Part D Under the standard 2026 Part D benefit, that coinsurance is 25% during the initial coverage phase.7CMS. Final CY 2026 Part D Redesign Program Instructions

The number that matters most is the annual out-of-pocket cap. In 2025 it was $2,000; for 2026 it rises to $2,100.8Medicare.gov. Part D Costs Once your deductible and coinsurance payments reach that threshold, you pay $0 for covered drugs for the rest of the calendar year.7CMS. Final CY 2026 Part D Redesign Program Instructions Branded Hyrimoz has a wholesale acquisition cost around $6,576 per unit, so at 25% coinsurance, most patients on adalimumab reach the cap within the first few months of the year.9PMC. Adalimumab Biosimilar Formulary Coverage in Medicare Part D Plans

One point worth knowing: because plans tier Humira and its biosimilars identically, your coinsurance on Hyrimoz is likely to be nearly the same as it would be on Humira.4PMC. Adalimumab Biosimilar Formulary Coverage in Medicare Part D The biosimilar’s lower price mostly benefits the plan, not your wallet.

How the 2026 Part D Phases Work

  • Deductible phase: you pay 100% of drug costs up to $615.
  • Initial coverage phase: you pay 25% coinsurance on covered drugs.
  • Catastrophic phase: once your out-of-pocket spending reaches $2,100, you pay $0 for the rest of the year.

The old coverage gap, the “donut hole,” is gone. Plans track your spending and move you into the catastrophic phase automatically.8Medicare.gov. Part D Costs

Spreading the Cost: Medicare Prescription Payment Plan

Reaching the cap in a single pharmacy visit can mean a bill of several hundred dollars at the counter. The Medicare Prescription Payment Plan lets you spread your annual drug costs into capped monthly installments with no interest. Every Part D plan must offer it.10Medicare.gov. What’s the Medicare Prescription Payment Plan The monthly amount recalculates each month based on your remaining balance and the months left in the year. You can enroll anytime by contacting your plan, and you can leave the program without losing your drug coverage.11CMS. Medicare Prescription Payment Plan

If Your Plan Doesn’t Cover Hyrimoz

You have a few paths.

Request a formulary exception. Your prescriber submits a statement explaining why covered alternatives would be less effective or cause adverse effects. Plans must decide standard requests within 72 hours and expedited requests within 24 hours.12CMS. Part D Exceptions A tiering exception, which asks the plan to charge a lower tier’s cost-sharing, is also available, though plans aren’t required to grant it for drugs on specialty tiers.13Medicare Interactive. Requesting a Tiering Exception

Switch plans at open enrollment. From October 15 through December 7, you can compare plans and move to one that covers Hyrimoz. Formularies change every year.

Consider another adalimumab biosimilar. Eight of the ten FDA-approved adalimumab biosimilars now carry interchangeability designations and are clinically equivalent to Humira.14Center for Biosimilars. Adalimumab Double Take: The Unexpected Return to Reference Humira Important boundary: biosimilars are interchangeable only with the reference product, Humira, not with each other. Switching from Hyrimoz to a different biosimilar requires a new prescription.4PMC. Adalimumab Biosimilar Formulary Coverage in Medicare Part D

Help Paying for Hyrimoz

Manufacturer copay coupons are not an option. Those are restricted to privately insured patients, and Medicare beneficiaries cannot use them.15Hyrimoz.com. Hyrimoz Patient Support Several other programs can.

Medicare Extra Help

Extra Help, also called the Low-Income Subsidy, eliminates the Part D premium and deductible for qualifying beneficiaries and caps copays at $12.65 per brand-name prescription in 2026. Once you reach the $2,100 out-of-pocket threshold, you pay $0 for covered drugs. In 2026, individuals with income up to $23,940 and resources up to $18,090 may qualify. If you receive full Medicaid, Medicare Savings Program assistance, or Supplemental Security Income, you’re enrolled automatically.16Medicare.gov. Get Help With Drug Costs

Sandoz Patient Assistance Program

Sandoz, which makes Hyrimoz, runs a Patient Assistance Program open to Medicare beneficiaries who meet income limits. For a single-person household, the 2023 income cap was $87,480. Enrolled patients get the medication at no cost for a calendar year, but during that time they cannot also fill Hyrimoz through their Part D plan or count the drug toward their out-of-pocket spending. The program’s line is 1-833-472-6369.17Sandoz. Hyrimoz Patient Assistance Program Income Requirements

Independent Copay Foundations

Nonprofit foundations help Medicare patients afford biologics for autoimmune conditions. Availability shifts with funding, so check more than one.

  • The PAN Foundation offers grants for rheumatoid arthritis and runs a FundFinder tool that tracks assistance across organizations. Apply at panapply.org or call 1-866-316-7263.18PAN Foundation. Rheumatoid Arthritis Fund
  • The HealthWell Foundation runs an AutoImmune Medicare Access fund with awards up to $2,800. The fund opens and closes depending on funding.19HealthWell Foundation. AutoImmune – Medicare Access
  • The Patient Advocate Foundation’s Co-Pay Relief program maintains disease-specific funds for conditions including rheumatoid arthritis, psoriasis, and psoriatic arthritis. Applications are at portal.copays.org.20Patient Advocate Foundation. Co-Pay Relief Program